Analysis of the status of the novel estrogen receptor α (ERα) coactivator p72 in endometrial cancer and its cross talk with erbB-2 in the transactivation of ERα

Molecular Medicine Reports

Volumn 1, Issue 3, 2008, Pages 387-390

  Zhao, Lin ^a   Watanabe, Michiko ^a   Yano, Tetsu ^a   Yanagisawa, Junn ^b   Nakagawa, Shunsuke ^a   Oishi, Hajime ^a   Wada Hiraike, Osamu ^a   Oda, Katsutoshi ^a   Minaguchi, Takeo ^a   Yasugi, Toshiharu ^a   Kato, Shigeaki ^c   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cofactor; Estrogen; p72; Receptor; Transactivation

Indexed keywords

17ALPHA ESTRADIOL; 4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PROTEIN P72; PROTEIN TYROSINE KINASE; STEROID RECEPTOR COACTIVATOR 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DIFFERENTIATION; TRANSACTIVATION; TRANSIENT EXPRESSION;

EID: 69249136665     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.3.387     Document Type: Article

References (27)

1. Beato M, Herrlich P and Schutz G: Steroid hormone receptors: many actors in search of plot. Cell 83: 851-857, 1995. (Pubitemid 26006527)
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995. (Pubitemid 126663112)
3. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954, 1996. (Pubitemid 26285969)
4. Lees JA, Fawell SE and Parker MG: Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res 17: 5477-5488, 1989.
5. Freedman PL: Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97: 5-8, 1999. (Pubitemid 29165883)
6. Onate SA, Tsai SY, Tsai MJ and O'Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357, 1995.
7. Voegel JJ, Heine MJ, Zechel C, Chambon P and Gronemeyer H: TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15: 3667-3675, 1996. (Pubitemid 26239779)
8. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968, 1997. (Pubitemid 27366683)
9. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK and Rosenfeld MG: The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387: 677-684, 1997. (Pubitemid 27270601)
10. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ and O'Malley BW: A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97: 17-27, 1999. (Pubitemid 29165886)
11. Bouras T, Southey MC and Venter DJ: Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 61: 903-907, 2001.
12. Lamm GM, Nicol SM, Fuller PF and Lamond AI: p72: a human nuclear DEAD box protein highly related to p68. Nucleic Acids Res 24: 3739-3747, 1996.
13. Watanabe M, Yanagisawa J, Kitagawa H, Takeyama K, Ogawa S, Arao Y, Suzawa M, Kobayashi Y, Yano T, Yoshikawa H, Masuhiro Y and Kato S: A subfamily of RNA binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J 20: 1341-1352, 2001. (Pubitemid 32233974)
14. Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H, Yanagisawa J, Metzger D, Hashimoto S and Kato S: Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol Cell Biol 19: 5363-5372, 1999. (Pubitemid 29339895)
15. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D and Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
16. Podratz KC, O'Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA and Edmonson JH: Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66: 106-110, 1985. (Pubitemid 15047395)
17. Creasman WT, Soper JT, McCarty KS Jr, McCarty KS Sr, Hinshaw W and Clarke-Pearson DL: Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151: 922-932, 1985.
18. Kauppila AJ, Isotalo HE, Kivinen ST and Vihko RK: Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 46: 5380-5384, 1986.
19. Pearl ML, Talavera F, Gretz HF III, Roberts JA and Menon KM: Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE. Gynecol Oncol 49: 325-332, 1993. (Pubitemid 23191205)
20. Lelle RJ, Talavera F, Gretz H, Roberts JA and Menon KM: Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer 72: 519-525, 1993. (Pubitemid 23193461)
21. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS and Podratz KC: HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47: 179-185, 1992. (Pubitemid 23001325)
22. Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C and Gitsch G: Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 98: 151-155, 1996. (Pubitemid 26010324)
23. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, Tobe K, Matsuda S, Tsushima T, Yamamoto T, Fujita T, Taketani Y, Fukayama M, Kimura S, Yazaki Y, Nagai R and Kadowaki T: Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem 275: 33937-33944, 1999. (Pubitemid 30808621)
24. Pecorelli S, Benedet JL, Creasman WT and Shepherd JH: FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 65: 243-249, 1999.
25. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA and Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937, 1998. (Pubitemid 29019045)
26. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, Askergren J and Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120, 1989. (Pubitemid 19034031)
27. Fisher B, Costantino JP, Redmond K, Fishe ER, Wickerham DL and Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1994. (Pubitemid 24111008)